Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26847060.
- Also identified by DOI 10.1158/1078-0432.CCR-15-3106 and PMC identifier 4818665.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The clinical success of agents targeting the B-cell receptor signaling pathway in chronic lymphocytic leukemia (CLL) may also derive from disrupting the CLL microenvironment. Investigation of the immunomodulatory effects of these agents illuminates the unique immunobiology of CLL and highlights potential targets for dismantling the chronic inflammatory drive. See related article by Niemann et al., p. 1572.
Medical subject headings
- Leukemia, Lymphocytic, Chronic, B-Cell
- Protein Kinase Inhibitors